Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors

被引:14
作者
Allen, Pamela B. [1 ,2 ]
Gordon, Leo I. [3 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, 676 North St Clair,Suite 850, Chicago, IL 60611 USA
[3] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
关键词
Hodgkin lymphoma; early unfavorable; early favorable; advanced stage; PET directed; prognosis; POSITRON-EMISSION-TOMOGRAPHY; RESPONSE-ADAPTED THERAPY; INVOLVED-FIELD RADIOTHERAPY; PET-DIRECTED THERAPY; STUDY-GROUP GHSG; PHASE-III TRIAL; INTERIM-PET; STANFORD V; HIGH-RISK; CYCLES;
D O I
10.1177/1179554917731072
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Thus, treatment has been refined through prognostic models and positron emission tomography-computed tomography (PET-CT)-directed therapy. Stratification by prognostic models defines groups of patients with favorable characteristics who may be treated with less intensive therapy upfront, including fewer cycles of chemotherapy, lower doses of radiation, or omission of radiation altogether. Alternatively, high-risk patients may be assigned to a more aggressive initial approach. The modern use of interim PET-CT allows further tailoring of treatment by response.
引用
收藏
页数:10
相关论文
共 55 条
[1]   Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial [J].
Advani, Ranjana H. ;
Hong, Fangxin ;
Fisher, Richard I. ;
Bartlett, Nancy L. ;
Robinson, K. Sue ;
Gascoyne, Randy D. ;
Wagner, Henry, Jr. ;
Stiff, Patrick J. ;
Cheson, Bruce D. ;
Stewart, Douglas A. ;
Gordon, Leo I. ;
Kahl, Brad S. ;
Friedberg, Jonathan W. ;
Blum, Kristie A. ;
Habermann, Thomas M. ;
Tuscano, Joseph M. ;
Hoppe, Richard T. ;
Horning, Sandra J. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1936-U111
[2]   Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial [J].
Andre, Marc P. E. ;
Girinsky, Theodore ;
Federico, Massimo ;
Reman, Oumedaly ;
Fortpied, Catherine ;
Gotti, Manuel ;
Casasnovas, Olivier ;
Brice, Pauline ;
van der Maazen, Richard ;
Re, Alessandro ;
Edeline, Veronique ;
Ferme, Christophe ;
van Imhoff, Gustaaf ;
Merli, Francesco ;
Bouabdallah, Reda ;
Sebban, Catherine ;
Specht, Lena ;
Stamatoullas, Aspasia ;
Delarue, Richard ;
Fiaccadori, Valeria ;
Bellei, Monica ;
Raveloarivahy, Tiana ;
Versari, Annibale ;
Hutchings, Martin ;
Meignan, Michel ;
Raemaekers, John .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) :1786-+
[3]  
[Anonymous], 2015, CLIN ADV HEMATOL ONC, V13, P16
[4]   Hodgkin lymphoma: 2014 Update on diagnosis, risk-stratification, and management [J].
Ansell, Stephen M. .
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (07) :772-779
[5]   Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma [J].
Avigdor, A. ;
Bulvik, S. ;
Levi, I. ;
Dann, E. J. ;
Shemtov, N. ;
Perez-Avraham, G. ;
Shimoni, A. ;
Nagler, A. ;
Ben-Bassat, I. ;
Polliack, A. .
ANNALS OF ONCOLOGY, 2010, 21 (01) :126-132
[6]   A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) [J].
Ballova, V ;
Rüffer, JU ;
Haverkamp, H ;
Pfistner, B ;
Müller-Hermelink, HK ;
Dühmke, E ;
Worst, P ;
Wilhelmy, M ;
Naumann, R ;
Hentrich, M ;
Eich, HT ;
Josting, A ;
Löffler, M ;
Diehl, V ;
Engert, A .
ANNALS OF ONCOLOGY, 2005, 16 (01) :124-131
[7]   PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study [J].
Barrington, Sally F. ;
Kirkwood, Amy A. ;
Franceschetto, Antonella ;
Fulham, Michael J. ;
Roberts, Thomas H. ;
Almquist, Helen ;
Brun, Eva ;
Hjorthaug, Karin ;
Viney, Zaid N. ;
Pike, Lucy C. ;
Federico, Massimo ;
Luminari, Stefano ;
Radford, John ;
Trotman, Judith ;
Fossa, Alexander ;
Berkahn, Leanne ;
Molin, Daniel ;
D'Amore, Francesco ;
Sinclair, Donald A. ;
Smith, Paul ;
O'Doherty, Michael J. ;
Stevens, Lindsey ;
Johnson, Peter W. .
BLOOD, 2016, 127 (12) :1531-1538
[8]  
Bauer K, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007941.pub2, 10.1002/14651858.CD007941]
[9]   Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG) [J].
Behringer, K ;
Diehl, V .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 :21-25
[10]   Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's lymphoma study group [J].
Behringer, K ;
Breuer, K ;
Reineke, T ;
May, M ;
Nogova, L ;
Klimm, B ;
Schmitz, T ;
Wildt, L ;
Diehl, V ;
Engert, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7555-7564